FILING ANALYSIS · FRIDAY, NOVEMBER 13
TuHURA Biosciences, Inc./NV HURA — 8-K: Results of Operations and Financial Condition
neutral
The company reported progress in its programs, including a first look at data from its open-label study of IFx-2.0 with Keytruda, and received FDA clearance to begin a Phase 1b study of TBS-2025, but no quantified surprises were disclosed, and the company has access to a $50mm credit facility from its largest shareholder, which is a non-dilutive financing option.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →